

DRUG PRIOR AUTHORIZATION COMMITTEE
December 14, 2017

AGENDA

James C. Kirkpatrick State Information Center
600 West Main Street
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Stephen Calloway/Mitch Ruth
10:25 - 10:35	DUR Update	Stephen Calloway

Old Business

10:35 – 10:45	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Stephen Calloway
---------------	--	------------------

New Business

10:45 – 11:30	B. Proposed Actions - New Drug/Product Review (See website and Attached Summary)	Stephen Calloway
---------------	--	------------------

- I. Open Access**
- II. Clinical Edit/Step Therapy**
- III. PDL Products**
- IV. Prior Authorization**
 - Discussion
 - Public Hearing
 - Decision

11:30 – 11:45

C. Clinical Edits

- I. Morphine Milligram Equivalents Accumulation**
 - Discussion
 - Public Hearing
 - Decision
- II. Benzodiazepines Clinical Edit**
 - Discussion
 - Public Hearing
 - Decision
- III. Atypical Antipsychotics Step Therapy Clinical Edit**
 - Discussion
 - Public Hearing
 - Decision

IV. Psychiatric Polypharmacy Clinical Edit

- Discussion
- Public Hearing
- Decision

V. Dose Optimization Clinical Edit

- Discussion
- Public Hearing
- Decision

VI. OTC/Dispensing Quantity Fiscal Edit

- Discussion
- Public Hearing
- Decision

11:45 – 1:00

D. Preferred Drug List (PDL)

I. Alzheimer's Agents

- Discussion
- Public Hearing
- Decision

II. Antiemetic Agents

- Discussion
- Public Hearing
- Decision

III. Antipsychotics: Long-Acting Injectables (NEW)

- Discussion
- Public Hearing
- Decision

IV. Cox-II Inhibitor Agents

- Discussion
- Public Hearing
- Decision

V. Fibromyalgia Agents

- Discussion
- Public Hearing
- Decision

VI. GI Motility Agents

- Discussion
- Public Hearing
- Decision

VII. Movement Disorder Agents (NEW)

- Discussion
- Public Hearing
- Decision

- VIII. Neuropathic Pain Agents**
 - Discussion
 - Public Hearing
 - Decision
- IX. Non-Ergot Dopamine Receptor Agonists**
 - Discussion
 - Public Hearing
 - Decision
- X. NSAID Agents**
 - Discussion
 - Public Hearing
 - Decision
- XI. Opioid Dependence Agents**
 - Discussion
 - Public Hearing
 - Decision
- XII. Opioid Emergency Reversal Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIII. Opioids, Long-Acting Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Sedative Hypnotic Agents**
 - Discussion
 - Public Hearing
 - Decision
- XV. Skeletal Muscle Relaxants**
 - Discussion
 - Public Hearing
 - Decision
- XVI. Serotonin Receptor Agonists (Triptans)**
 - Discussion
 - Public Hearing
 - Decision
- XVII. Tramadol-Like Agents**
 - Discussion
 - Public Hearing
 - Decision

E. Proposed NEW Preferred Drug List Classes

F. Preferred Drug List Classes for March/April

- I. Process Discussion
- II. Therapeutic classes/to be announced at meeting

1:00-1:30	LUNCH	
1:15-1:30	Program Utilization Information Conduent Update	Stephen Calloway/ Luke Boehmer
1:30-1:50	Other Business	
	<ul style="list-style-type: none">▪ <i>“Top 25” Drugs by Cost/Claims</i>▪ <i>Clinical Edit Summary Report</i>▪ <i>Call Center Statistics</i>	

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: Thursday, March 15, 2018
Department of Natural Resources - 1101 Riverside Dr.
Lacharrette/Nightengale Rooms